R
Ryder System, Inc.
R
Ryder System, Inc.
Ryder System, Inc. remains a Buy as management drives revenue and profitability growth, with shares still trading at low multiples. Strategic focus on value-added services and shifting revenue mix tow
Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic m
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the
Ryder System NYSE: R reported its seventh consecutive quarter of comparable earnings-per-share growth, with management pointing to contractual revenue, strategic initiatives and improving used vehicle